Literature DB >> 2225318

Phase II trial of carboplatin and vinblastine in advanced squamous-cell carcinoma of the head and neck.

S El-Sayed1, R P Symonds, A G Robertson, J Paul, J McGarva.   

Abstract

A chemotherapy regimen consisting of carboplatin and vinblastine was given to 30 patients with recurrent or previously untreated, locally advanced squamous carcinoma of the head and neck region. The main aim of the study was to assess the toxicity of this regimen, the feasibility of its outpatient administration and the tumour response. A total of ten patients (33%) achieved an objective response, including two who achieved a complete response. The combination offered useful palliation for patients with recurrent disease; it was well tolerated and can be given on an outpatient basis. This regimen could be combined with other active agents such as methotrexate or bleomycin.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2225318     DOI: 10.1007/bf02994101

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  12 in total

Review 1.  Integration of chemotherapy into a combined modality treatment plan for head and neck cancer: a review.

Authors:  J H Glick; S G Taylor
Journal:  Int J Radiat Oncol Biol Phys       Date:  1981-02       Impact factor: 7.038

2.  Ovarian trials at the Royal Marsden.

Authors:  E Wiltshaw
Journal:  Cancer Treat Rev       Date:  1985-09       Impact factor: 12.111

Review 3.  The chemotherapy of head and neck cancer.

Authors:  S K Carter
Journal:  Semin Oncol       Date:  1977-12       Impact factor: 4.929

4.  Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck.

Authors:  M Eisenberger; J Hornedo; H Silva; R Donehower; M Spaulding; D Van Echo
Journal:  J Clin Oncol       Date:  1986-10       Impact factor: 44.544

5.  Carboplatin, an active drug in advanced head and neck cancer.

Authors:  L de Andres Basauri; A Lopez Pousa; E Alba; F Sampedro
Journal:  Cancer Treat Rep       Date:  1986-10

6.  Reporting results of cancer treatment.

Authors:  A B Miller; B Hoogstraten; M Staquet; A Winkler
Journal:  Cancer       Date:  1981-01-01       Impact factor: 6.860

7.  Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck.

Authors:  J A Kish; A Weaver; J Jacobs; G Cummings; M Al-Sarraf
Journal:  Cancer       Date:  1984-05-01       Impact factor: 6.860

8.  A randomized trial of the combination of cis-platinum, oncovin and bleomycin (COB) versus methotrexate in patients with advanced squamous cell carcinoma of the head and neck.

Authors:  A Drelichman; G Cummings; M Al-Sarraf
Journal:  Cancer       Date:  1983-08-01       Impact factor: 6.860

9.  Methotrexate treatment of squamous-cell head and neck cancers: dose-response evaluation.

Authors:  R L Woods; R M Fox; M H Tattersall
Journal:  Br Med J (Clin Res Ed)       Date:  1981-02-21

10.  A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group.

Authors:  M Adams; I J Kerby; I Rocker; A Evans; K Johansen; C R Franks
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

View more
  1 in total

Review 1.  Programmed cell death, redox imbalance, and cancer therapeutics.

Authors:  Xiaofeng Dai; Danjun Wang; Jianying Zhang
Journal:  Apoptosis       Date:  2021-07-08       Impact factor: 4.677

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.